The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2018 Mar 9

PMID 29516490

Citations 18

Authors

Jason N Moore

Marc R Gastonguay

Chee M Ng

Susan C Adeniyi-Jones

David E Moody

Wenfang B Fang

Michelle E Ehrlich

Walter K Kraft

Affiliations

Soon will be listed here.

Abstract

Neonatal abstinence syndrome (NAS) is a condition affecting newborns that are exposed to an opioid in utero. In a randomized, controlled trial assessing the efficacy of buprenorphine and morphine in NAS, blood samples were analyzed from a subset of patients receiving buprenorphine along with NAS scores. The data were used to validate and adapt an existing model of buprenorphine in neonates and to identify relationships between buprenorphine or norbuprenorphine pharmacokinetics (PK) and efficacy or safety. The time to NAS stabilization was found to decrease with increasing buprenorphine exposure. This pharmacokinetic-pharmacodynamic (PK-PD) relationship was able to be quantified and adequately described with a mathematical model. The findings confirm a previous PK model of buprenorphine and extend the model to describe the PK of norbuprenorphine and to identify a novel PK-PD relationship of buprenorphine in NAS. This model will allow optimization of dosing strategies in future clinical trials.

Citing Articles

Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome.

Lam K, Mondick J, Peltz G, Wu M, Kraft W Clin Transl Sci. 2025; 18(2):e70147.

PMID: 39930952 PMC: 11811511. DOI: 10.1111/cts.70147.

Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study.

Anbalagan S, Anderson V, Favara M, Stark D, Carola D, Solarin K J Perinatol. 2024; .

PMID: 39003405 DOI: 10.1038/s41372-024-02046-7.

Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.

van Hoogdalem M, Tanaka R, Johnson T, Vinks A, Mizuno T Drug Metab Dispos. 2024; 52(8):785-796.

PMID: 38769016 PMC: 11257693. DOI: 10.1124/dmd.124.001643.

Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling.

van Hoogdalem M, Tanaka R, Abduljalil K, Johnson T, Wexelblatt S, Akinbi H Pharmaceutics. 2024; 16(3).

PMID: 38543269 PMC: 10975492. DOI: 10.3390/pharmaceutics16030375.

The Finnegan Score for Neonatal Opioid Withdrawal Revisited With Routine Electronic Data: Retrospective Study.

Rech T, Rubarth K, Buhrer C, Balzer F, Dame C JMIR Pediatr Parent. 2024; 7:e50575.

PMID: 38456232 PMC: 11004517. DOI: 10.2196/50575.

References

Kraft W, Adeniyi-Jones S, Chervoneva I, Greenspan J, Abatemarco D, Kaltenbach K . Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med. 2017; 376(24):2341-2348. PMC: 5662132. DOI: 10.1056/NEJMoa1614835. View

Fleming S, Thompson M, Stevens R, Heneghan C, Pluddemann A, Maconochie I . Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011; 377(9770):1011-8. PMC: 3789232. DOI: 10.1016/S0140-6736(10)62226-X. View

Ko J, Patrick S, Tong V, Patel R, Lind J, Barfield W . Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013. MMWR Morb Mortal Wkly Rep. 2016; 65(31):799-802. DOI: 10.15585/mmwr.mm6531a2. View

Patrick S, Schumacher R, Benneyworth B, Krans E, McAllister J, Davis M . Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012; 307(18):1934-40. DOI: 10.1001/jama.2012.3951. View

Kaltenbach K, Jones H . Neonatal Abstinence Syndrome: Presentation and Treatment Considerations. J Addict Med. 2016; 10(4):217-23. DOI: 10.1097/ADM.0000000000000207. View

Kraft W, Gibson E, Dysart K, Damle V, Larusso J, Greenspan J . Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008; 122(3):e601-7. PMC: 2574639. DOI: 10.1542/peds.2008-0571. View

Kuhlman Jr J, Levine B, Johnson R, Fudala P, Cone E . Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 1998; 93(4):549-59. DOI: 10.1046/j.1360-0443.1998.93454910.x. View

Patrick S, Kaplan H, Passarella M, Davis M, Lorch S . Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011. J Perinatol. 2014; 34(11):867-72. DOI: 10.1038/jp.2014.114. View

Lam J, Baello S, Iqbal M, Kelly L, Shannon P, Chitayat D . The ontogeny of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. Pediatr Res. 2015; 78(4):417-21. DOI: 10.1038/pr.2015.119. View

10.

Brown S, Campbell S, Crafford A, Regina K, Holtzman M, Kharasch E . P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J Pharmacol Exp Ther. 2012; 343(1):53-61. PMC: 3464040. DOI: 10.1124/jpet.112.193433. View

11.

Huang W, Moody D, McCance-Katz E . The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther Drug Monit. 2006; 28(2):245-51. DOI: 10.1097/01.ftd.0000197094.92559.b4. View

12.

Bergstrand M, Hooker A, Wallin J, Karlsson M . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13(2):143-51. PMC: 3085712. DOI: 10.1208/s12248-011-9255-z. View

13.

Laffont C, Gomeni R, Heidbreder C, Jones 3rd J, Nasser A . Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder. J Clin Pharmacol. 2015; 56(7):806-15. DOI: 10.1002/jcph.665. View

14.

Yano Y, Beal S, Sheiner L . Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001; 28(2):171-92. DOI: 10.1023/a:1011555016423. View

15.

Hudak M, Tan R . Neonatal drug withdrawal. Pediatrics. 2012; 129(2):e540-60. DOI: 10.1542/peds.2011-3212. View

16.

Ng C, Dombrowsky E, Lin H, Erlich M, Moody D, Barrett J . Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy. 2015; 35(7):670-80. PMC: 5119858. DOI: 10.1002/phar.1610. View

17.

Hall E, Isemann B, Wexelblatt S, Meinzen-Derr J, Wiles J, Harvey S . A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. J Pediatr. 2015; 170:39-44.e1. DOI: 10.1016/j.jpeds.2015.11.039. View

18.

Keizer R, Karlsson M, Hooker A . Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e50. PMC: 3697037. DOI: 10.1038/psp.2013.24. View

19.

Tolia V, Patrick S, Bennett M, Murthy K, Sousa J, Smith P . Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015; 372(22):2118-26. DOI: 10.1056/NEJMsa1500439. View

20.

Osborn D, Jeffery H, Cole M . Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2010; (10):CD002059. DOI: 10.1002/14651858.CD002059.pub3. View